Cidara is pursuing a balanced infectious disease-focused development strategy intended to transform standards of care and save lives.

Rezafungin

Phase 1

Phase 2

Phase 3

Treatment

Treatment of Candidemia and Invasive Candidiasis

Phase 3 Planned Mid-2018

65%

Phase 3 Planned Mid-2018

Prophylaxis

Prophylaxis for Candida, PCP and Aspergillus in alloBMT

Phase 3 Planned Mid-2018

65%

Phase 3 Planned Mid-2018

Cloudbreak

Research

IND Enabling

Phase 1

ADC

Large Molecule Treatment and Prophylaxis Gram (-) Bacteria

Research

20%

Research Phase

GET IMPORTANT NEWS AND UPDATES BY EMAIL